+34 679 490 537info@nanbiosis.com

News U25

NANBIOSIS Scientific Women in the International Day of Women and Girls in Science

Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology.

According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science.

NANBIOSIS wants to acknowledge  the efforts made by scientific women who struggle every day to contribute their bit to Science and highlight their essential role in nowadays research. Especially we want to recognize the work of scientists women involved in our units, whatever is the nature of their contribution: technical, scientific development, management, coordination, direction, etc; just to mention some examples:
Neus Ferrer in the Scientific Direction of Unit 1 Protein Production Platform (PPP)
Pilar Marco and Nuria Pascual in the Management and Scientific Coordination of U2 Custom Antibody Service (CAbS) 
Miriam Royo in the Scientific Direction of U3 Synthesis of Peptides Unit
Laura Lechuga and M.Carmen Estevez in the Direction and Scientific Coordination of U4 Biodeposition and Biodetection Unit
Nora Ventosa and Nathaly Segovia in the Scientific Direction and Technical Coordination of U6 Biomaterial Processing and Nanostructuring Unit
Isabel Oliveira and Teresa Galán in the Coordination of U7 Nanotecnology Unit
Rosa Villa and Gemma Gabriel in the Management and Scientific Coordination of U8 Micro – Nano Technology Unit
Gema Martínez in the Scientific Coordination of U9 Synthesis of Nanoparticles Unit
Fany Peña in the Scientific Coordination of U13 Tissue & Scaffold Characterization Unit
Mª Luisa González Martín in the of Direction and Scientific Coordination of U16 Tissue & Scaffold Characterization Unit
Gemma Pascual and Isabel Trabado in the Coordination of the U17 Confocal Microscopy Service
Mª Virtudes Céspedes in the Scientific Coordination of U18 Nanotoxicology Unit
Beatriz Moreno in the Scientific Direction of Unit 19 Clinical tests lab
Ibane Abásolo in the Scientific Coordination of Unit 20 In Vivo Experimental Platformt
Verónica Crisóstomo in the Scientific Direction of Unit 24 Medical Imaging 

Ana Paula Candiota in the Scientific Coordination of Unit 25 Biomedical Applications I 
Maria Luisa García in the Scientific Direction of U28 NanoImaging Unit from Bionand, recently incorporated to NANBIOSIS

Read More

NANBIOSIS Against Cancer

The World Health Organization, the International Cancer Research Center (IARC) and the International Union Against Cancer (UICC) celebrate February 4 of each year as World Cancer Day

Every year, 14 million new cases of cancer are diagnosed worldwide and the disease causes 8.2 million deaths.

Thanks to scientific research, great advances have been made in the fight against cancer. Through surgery, chemotherapy or radio therapy and, in the last 20 years, through immunotherapy, hormonal treatment or cell therapies, tools have been obtained to improve early diagnosis and treatments, increasing cancer survival by 20%.

The only way to understand cancer and, someday, eradicate it or eliminate the suffering and death due to this disease, is RESEARCH

NANBIOSIS as an ICTS (Singular Scientific and Technical Infrastructures) for biomedical research plays a very important role in the fight against cancer. Some examples are bellow:

Thanks to a coordinated action between units U1 of Protein Production Platform (PPP), U18 of Nanotoxicology and U29 of Nucleic Acid Synthesis, NANBIOSIS is developing nanopharmaceuticals with a high degree of efficacy for the treatment of metastases in colon cancer, by using of proteins with high specificity of binding to metastatic cells and a high degree of permanence in the blood flow, loaded with anti-cancer drugs that are selectively released inside the tumor cells that are going to form the metastases. Through the public financing of a NEOTEC project and a RETOS-COLABORACION and the company NANOLIGENT SL, the first antimetastatic drug on the market will be developed.

The Protein Production Platform-PPP collaborates with research projects whose objective is the development of new cancer therapies based on recombinant modular proteins with the ability to self-assemble. These multimeric complexes have shown, in animal models, a high stability in serum and an improved biodistribution compared to that observed with drugs for clinical use. These principles have been valued in different types of cancer, including colorectal cancer and breast cancer. The modular design of these constructions allows the incorporation or substitution of direct peptides and therefore they are presented as a transversal tool for more effective treatments against cancer. In addition, the PPP has served the Vall d’Hebron Institute of Oncology (VHIO) of Barcelona, the Josep Vilanueva group (CIBERONC) in the field of biomarker study and new targets associated with triple negative breast cancer (TNBC).

Unit 6 of NANBIOSIS Biomaterial Processing and Nanostructuring Unit is working on a project in collaboration with VHIR, financed by the Spanish Goverment and CIBER-BBN, for the development of a new nanomedicine for the treatment of high-risk neuroblastoma, one of the most frequent childhood cancers.

Unit 6 is also working on the project Artificial Lymph Nodes for Cancer ImmunoTherapy (ALYCIA) A project born of a initiative of CIBER-BBN/ CIBERONC to enhance scientific interdisciplinary collaborations between research groups working on oncology and nanomedicine. Researchers of unit 6 will develop Artificial Lymph Nodes (ALN) based on dynamic 3D scaffolds able to promote efficient ex vivo lymphatic cell expansion of relevant phenotypes. Such ALN represent a new approach to lymphocyte expansion, which not only includes artificial Antigen Presenting Cells in suspension like the state-of-the-art expansion techniques, but also mimics the function of the LN ex vivo.

One of the singular capabilities of the U25 of NANBIOSIS NMR: Biomedical Applications I is the acquisition of high quality, high resolution preclinical magnetic resonance imaging/spectroscopy/spectroscopic imaging data. This allows performing leading-edge studies in preclinical cancer models such as noninvasive therapy response follow-up in murine brain tumours, revealing new response biomarkers with translational potential for brain cancer patients.

NANBIOSIS U4 Biodeposition and Biodetection Unit  is currently developing the national project PREDICT Point-of-care Nanoplasmonic Platforms for Novel High-Value Diagnostics and Therapy Follow-Up , which works in the early detection of lung cancer. PREDICT project will use the Unit 4 of Nanbiosis for the multiplexed biofunctionalization of the biosensor chips and their methodology optimisation.

Finally, Unit 20 of NANBIOSIS In Vivo Experimental Platform at VHIR, is the most implicated of the CIBER units on projects in the field of cancer, just to name some of them: H2020-NoCanTher: magnetic nanoparticles against pancreatic cancer through the use of hyperthermia combined with conventional treatment. H2020-Target-4-Cancer: nanotherapy based on polymeric micelles directed against specific receptors of tumor stem cells in colorectal cancer. H2020-DiamStar: nanodiamonds directed against leukemia for the potentiation of chemotherapy. FET-OPEN EvoNano: in silico and tumor-tumor models for the prediction of PK / PD and tumor efficacy of antitumor nanomedicines against tumor stem cells. FIS-ISCIII: polymeric micelles for siRNA and combined therapy against breast cancer tumor stem cells. CarboXigel: hydrogels for the sustained release of chemotherapeutic drugs against the metastatic spread of ovarian cancer. MelanoMir: nanomedicine applied to skin cancer, melanoma, beside other projects promoted by CIBER-BBN.

Read More

Cancer metabolism in a snapshot: MRS(I)

Margarida Julià‐Sapé, Ana Paula Candiota and Carles Arús, Scientific Director and Scientific Coordinators of Nanbiosis U25 NMR: Biomedical Applications I, are the authors of a new article in the journal NMR in Biomedicine: “Cancer metabolism in a snapshot: MRS(I)

The article contains a revision of the contribution of MRS(I) to the in vivo evaluation of cancer‐metabolism‐derived metrics, mostly since 2016. Strategies include the following: (1) quantification of single oncometabolite content such as 2HG; (2) selected metabolite ratios such as total Cho to NAA in gliomas, ratios related to Cho, Cr, citrate and polyamines in prostate cancer or Lac/Pyr in hyperpolarized 13C MRSI; and (3) the whole 1H MRSI(I) pattern, through pattern recognition analysis, allowing detection of response to therapy in preclinical brain tumours before detectable volume changes.

Read More

Preclinical Study for Brain Tumor with Novel Contrast Agents for MRI

Ana Paula Candiota and Carles Arús, Scientific Cordinator and Scientific Director of  U25 of NANBIOSIS, NMR: Biomedical Applications I  have participated in the research published by ACS Applied Materials & Interfaces Journal  that include a preclinical study carried for brain Tumor.

Extensive attention has been paid on designing and developing functional imaging contrast agents for providing accurate noninvasive evaluation of pathology in vivo. However, alse-positives or ambiguous imaging and the lack of a robust strategy for simultaneous dual-mode imaging remain to be fully addressed. One effective strategy for improving it is to  design magnetic resonance imaging (MRI) contrast agents (CAs) with intrinsic T1/ T2 dual-mode imaging features. In this joint work from ICN2 and CIBER-BBN members, the development and characterization of nanostructured coordination polymers (NCPs) which exhibit dual mode T1/ T2 MRI contrast behavior is described.

The MR characterization was performed at U25 of NANBIOSIS

Article of reference:

Dual T1/T2 Nanoscale Coordination Polymers as Novel Contrast Agents for MRI: A Preclinical Study for Brain Tumor“. S. Suárez-GarcíaN. Arias-RamosC. FriasA. P. CandiotaC. ArúsJ. LorenzoD. Ruiz-Molina, and F. Novio ACS Applied Materials & Interfaces Article ASAP

DOI: 10.1021/acsami.8b15594.

Read More

Nosological images of response to therapy based on metabolomic information by magnetic resonance

Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25. NMR: Biomedical Applications I. is givin a talk about “Nosological images of response to therapy based on metabolomic information by magnetic resonance: a step beyond the standard image” next June 6, on Barcelona.

According to Dr. Candiota, “The reliable characterization of the treatment response in glioblastoma (GB) is a key factor in improving the survival and prognosis of patients. Image (MRI) and spectroscopic image (MRSI) by magnetic resonance respectively provide morphological and metabolotic profiles of GB, but in general they are not as robust to produce surrogate biomarkers in response to short-term therapy. One of our objectives is to try to provide clinicians with a reliable way to follow the response to therapy in a more adjusted temporal window for changes or adaptations of the therapy, and in a more early way than the one currently performed using MRI.  This part of the course will emphasize the potentiality of the systems of patterrn recognition / machine learning to produce ‘nosological images’ to recognize in a robust way the response to temozolamide (TMZ) therapy in preclinical GB (glioblastoma GL261 murine model in the immunocompetent strain C57 / BL / 6), based on the information of the magnetic resonance spectroscopic images. Despite being developed on a preclinical model of pathology, these techniques have a clear translational potential and could in the future improve the management of the different aspects of the treatment of patients”.

The talk will take place in the Conference: Nanotechnology applied to medicine as a learning resource for healthcare professionals, organized by Union Consorci Formació in Barcelona (Parc Sanitari Pere Virgili, Edifici Montseny planta -1).

The objective of the event is to summarize the most significant advances that have been made in this field, both at the level of development of nanomaterials, as well as in the most relevant applications of the different nano-pharmaceuticals that are on the market, to end up highlighting the future challenges to which faces nanomedicine to increase the efficiency and specificity of nanomedication.

Programa e inscripciones: Inscription is free  but the number of places is limited.

Read More

New book coauthored by Scientists of @NANBIOSIS U25 on Preclinical MRI

Silvia Lope-Piedrafita and Nuria Arias Ramos, Scientists of NANBIOSIS U25 NMR: Biomedical Applications I, have participated as co-authors in chapters of the book “Preclinical MRI – Methods and Protocols“. Editors: María Luisa García Martín y Pilar López Larrubia.

This book, also co-authored by other researchers of CIBER-BBN, as Guadalupe Soria y Raul Tudela,  is organized into 7 parts :

-Part 1 covers the basics of MRI physics, relaxation, image contrast, and main acquisition sequences;

-Part 2 describes methodologies for diffusion, perfusion, and functional imaging;

-Part 3 looks at in vivo spectroscopy;

-Part 4 explores special MRI techniques that are less known in the field;

-Parts 5 and 6 discuss MRIs and MRSs in animal models of disease and the applications used to study them, and

-Part 7 looks at anesthesia and advanced contrast agents.

Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.

Read More

Ana Paula Candiota member of the Panel of experts from the Autonomous University of Barcelona.

Ana Paula Candiota, Scientific Coordinator of NANBIOSIS U25. NMR: Biomedical Applications I, is now part of the Panel of experts from the Autonomous University of Barcelona. This panel aims to offer their knowledge and experience to the media in case they have questions on specific issues.

Read More

Posters presentation by NANBIOSIS Units in CIBER-BBN ANNUAL CONFERENCE 2017

Last 13 and 14 of November, CIBER-BBN  has celebrated its 11th Annual Conference in Hotel Santemar in Santander. In this conference there was a poster session with the participation of the following Units of NANBIOSIS. Special mention deserves Unit 1 with Neus Ferrer as Director and  Paolo Saccardo as Coordinator (in the picture):

Posters:

U1. Protein Production Platform (PPP):

Engineering protein complexes as nano- or micro-structured vehicles or drugs for human and veterinary medicine. Ugutz Unzueta, Naroa Serna, Laura Sánchez-García, José Vicente Carratalá, Olivia Cano-Garrido, Mercedes Márquez, Paolo Saccardo, Rosa Mendoza, Raquel Díaz, Héctor, López-Laguna, Julieta Sánchez, Anna Obando, Amanda Muñoz, Andrés Cisneros, Eric Voltà, Aida Carreño, José Luis Corchero, Neus Ferrer-Miralles, Esther Vázquez, Antonio Villaverde.

Units  U1. Protein Production Platform (PPP) and U18. Nanotoxicology Unit:

Intrinsic functional and architectonic heterogeneity of tumor-targeted protein nanoparticles. Mireia Pesarrodona, Eva Crosa, Rafael Cubarsi, Alejandro Sanchez-Chardi, Paolo Saccardo, Ugutz Unzueta, Fabian Rueda, Laura Sanchez-Garcia, Naroa Serna, Ramón Mangues, Neus Ferrer Miralles, Esther Vázquez, Antonio Villaverde.

Units U3. Synthesis of Peptides UnitU6. Biomaterial Processing and Nanostructuring Unit, and U20. In Vivo Experimental Platform:

Synthesis of different length monodisperse COL-PEG-PEPTIDE to increase biodisponibility of multifunctional nanovesicles for Fabry’s desease. Edgar Cristóbal-Lecina; Daniel Pulido; Solène Passemard; Elizabet González-Mira; Jaume Veciana; Nora Ventosa; Simó Schwartz; Ibane Abasolo; Fernando Albericio and Miriam Royo.

Units U13. Tissue & Scaffold Characterization Unit and U17. Confocal Microscopy Service::

Preclinical behavior of medium-chain cyanoacrylate glue with two different surgical application forms for mesh fixation in abdominal wall repair. Gemma Pascual, Bárbara Pérez-Köhler, Marta Rodríguez, Claudia Mesa-Ciller, Ángel Ortillés, Estefanía Peña, Begoña Calvo, Juan M. Bellón.

Units U27. High Performance Computing and U8. Micro – Nano Technology Unit:

Inspiration and Expiration Dynamics in Acute Emotional Stress Assessment. Javier Milagro, Eduardo Gil, Jorge M. Garzón-Rey, Jordi Aguiló, Raquel Bailón.

U5. Rapid Prototyping Unit:

Poly-DL-lactic acid films functionalized with collagen IV as carrier substrata for corneal epithelial stem cells. Ana de la Mata, Miguel Ángel Mateos-Timoneda, Teresa Nieto-Miguel, Sara Galindo, Marina López-Paniagua, Xavier Puñet, Elisabeth Engel, Margarita Calonge.

U6. Biomaterial Processing and Nanostructuring Unit:

Strategy for engineering myoglobin nano-traps for biomedical sensing technology. E. Laukhina, O. V. Sinitsyna, N. K. Davydova, V. N. Sergeev, A. Gomez, I. Ratera, C. Blázquez Bondia, J. Paradowska, X. Rodriguez, J. Guasch, Jaume Veciana.

Structure and nanomechanics of quatsome membranes. B. Gumí-Audenis, L. PasquinaLemonche, J.A. Durán, N. Grimaldi, F. Sanz, J. Veciana, I. Ratera, N. Ventosa and M.I. Giannotti

U7. Nanotechnology Unit:

Bioreceptors nanostructuration study for early detection of Alzheimer. José Marrugo, Dr. Samuel Dulay, Dr. Mònica Mir, Prof. Josep Samitier.

RGD dendrimer-based nanopatterns promote chondrogenesis and intercellular communication for cartilage regeneration. Ignasi Casanellas, Anna Lagunas, Iro Tsintzou, Yolanda Vida, Daniel Collado, Ezequiel Pérez-Inestrosa, Cristina Rodríguez, Joana Magalhães, José A. Andrades, José Becerra, Josep Samitier.

Long-range electron transfer between redox partner proteins. Anna Lagunas, Alejandra GuerraCastellano, Alba Nin-Hill, Irene Díaz-Moreno, Miguel A. De la Rosa, Josep Samitier, Carme Rovira, Pau Gorostiza.

U8. Micro – Nano Technology Unit:

Miniaturized multi-sensing platform for pH and Dissolved Oxygen monitoring in Organ-On-aChip systems. M. Zea, A. Moya, I. Gimenez, R. Villa, G. Gabriel.

Electrochemical characterization of SWCNTs based microelectrodes fabricated by inkjet printing. M. Mass, A. Moya, G. Longinotti, M. Zea, M. Muñoz, E. Ramon, L. Fraigi, R. Villa, G. Ybarra, G. Gabriel.

U9. Synthesis of Nanoparticles Unit:

In vivo imaging and local persistance of polymeric micro- and nanomaterials labelled with the near infrared dye IR820. Isabel Ortiz de Solórzano, Gracia Mendoza, Inmaculada Pintre, Sara García-Salinas, Víctor Sebastián, Vanesa Andreu, Marina Gimeno, Manuel Arruebo.

U10. Drug Formulation:

Cationic nioplexes-in-polysaccharide-based hydrogels as versatile biodegradable hybrid materials to deliver nucleic acids. Santiago Grijalvo, Adele Alagia, Gustavo Puras, Jon Zárate, Judith Mayr, José Luis Pedraz, Ramon Eritja

U12. Nanostructured liquid characterization unit:

Perfluorocarbon-loaded Nanocapsules from Nano-emulsion Templates as Microbubble Precursors for Biomedical Applications. G. Calderó, A. González, M. Monge, C. Rodríguez-Abreu, M.J.García-Celma, C. Solans.

Biodistribution study of polymeric drug-loaded nanoparticles in murine model. Marta Monge, Aurora Dols, Stephane Fourcade, Aurora Pujol, Carlos Rodríguez-Abreu, Conxita Solans.

U16. Surface Characterization and Calorimetry Unit:

Behavior and a comparative study between tantalum and titanium alloy implant surfaces against bacterial adhesion. M.A. Pacha-Olivenza, M.L. González-Martín.

Bacterial adhesion on calcium ion-modified titanium implant surfaces. M.A. Pacha Olivenza, R. Tejero, M. Delgado-Rastrollo, M.L. González-Martín.

Bioactive coatings to promote tissue regeneration and ingrowth into 3D custom-made porous titanium endoimplants (COATREG-3D). Santos-Ruiz L; Granados JF; Ruiz F; Yáñez JI; González A; Cabeza N; Vida Y; Pérez-Inestrosa E; Izquierdo-Barba I; Vallet-Regí M; Rubio J; Orgaz F; Rubio N; González ML; Peris JL; Monopoli D; Becerra J.

U17. Confocal Microscopy Service:

Subcutaneous implantation of a biodegradable apatite/agarose scaffold: biocompatibility and osteogenesis characterization in a rat model. Natalio García-Honduvilla, Gemma Pascual, Miguel A. Ortega, Alejandro Coca, Cynthia Trejo, Jesús Román, Juan Peña, María V. Cabañas, Julia Buján, and María Vallet-Regí.

U25. NMR: Biomedical Applications I:

Dual T1/T2 NCP-based novel contrast agents for brain tumor MRI: a preclinical study. Suarez, S; Arias-Ramos, N; Candiota, AP; Lorenzo, J; Ruiz-Molina, D; Arús, C; Novio, F.

Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide. Ferrer-Font, L; Arias-Ramos, N; Lope-Piedrafita, S; Julià- Sapé, M; Pumarola, M; Arús, C; Candiota, AP.

U26. NMR: Biomedical Applications II:

Gated nanodevices for innovative medical therapies. Maria Alfonso, Irene Galiana, Beatriz Lozano, Borja Diaz de Greñu, Cristina de la Torre, Andrea Bernardos, Sameh El Sayed, Daniel MuñozEspin, Miguel Rovira, José Ramón Murguía, Manuel Serrano, Ramón Martínez-Máñez.

NANOPROBE: Gated sensing materials and devices for the detection of infectious diseases and urological cancer. Ángela Ribes, Luís Pla, Sara Santiago-Felipe, Alba Loras-Monfort, M.Carmen Martínez-Bisbal, Elena Aznar, Guillermo Quintás-Soriano, José Luis Ruiz-Cerdá, María Angeles.

 

 

 

Read More

Unit 25 of NANBIOSIS and the research field of Protein Kinase CK2. 

Ana Paula Candiota and Carles Arús, Scientific Coordinator and Scientific Director of Unit 25 of NANBIOSIS, jointly with other GABRMN members, have recently published an interesting article in the journal Pharmaceuticals, (Special Issue An Updated View on an Emerging Target: Selected Papers from the 8th International Conference on Protein Kinase CK2). This article  is also co-authored by scientifics of a research group with renowned prestige in CK2 research field, the Protein Phosphorylation group, del Dipartimento di scienze biomediche (Università degli Studi di Padova).

This publication describes a study with the preclinical glioblastoma (GB) model and its treatment, centered in exploring the potential of other therapeutic (non-mutagenic) alternatives for preclinical GB. The results obtained suggest that Protein Kinase CK2 could be a suitable candidate target for GB treatment, which could be useful in combined treatments with temozolomide (TMZ), the standard of care currently used in clinics. Tumor-bearing animals under treatment were followed up with techniques of MRI, MRSI and DWI, and an interesting finding was the appearance of peritumoral brain edema in treated animals.

The acquisition and processing of MRI/MRSI/DWI data were performed in Unit 25 of NANBIOSIS

Article of reference:

Ferrer-Font, L.; Villamañan, L.; Arias-Ramos, N.; Vilardell, J.; Plana, M.; Ruzzene, M.; Pinna, L.A.; Itarte, E.; Arús, C.; Candiota, A.P. Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice. Pharmaceuticals 2017, 10, 24.

Read More

MRSI-based generation of nosological images for noninvasive therapy response assessment in preclinical GBM

Nuria Arias Ramos from GABRMN-UAB, research group coordinator of Unit 25 of NANBIOSIS, presented on January 30th, an oral communication at the youngSMIN | young Spanish Molecular Imaging Network Meeting.

The title of the communication is “Multi slice MRSI-based generation of nosological images for noninvasive therapy response assessment in preclinical GBM”, written by Nuria Arias-Ramos, SilviaLope-Piedrafita, Victor Mocioiu, Margarida Julià-Sapé, Carles Arús and Ana Paula Candiota.

The work is basically centered in extending the preliminary GABRMN study based on MRSI  acquired in a preclinical glioblastoma (GB), both under treatment and control, with pattern recognition and source extraction for noninvasive therapy response assessment. The preliminary study was  performed in a single tumoral slice, but the GB is a well-known heterogeneous tumor and also presents heterogenous response to treatment, so the multislice acquisition was an important step in order to characterize therapy response assessment as a whole, not centered in a single slice. Tumors were stratified in no response, partial response and high response after calculating the percentage of the ‘responding’ part of the tumor, and histopathological studies for correlation are in progress.

The MRSI acquisition and processing steps were performed in NANBIOSIS facility U25.

MRSI-based generation of nosological images for noninvasive therapy response assessment in preclinical GBM
Read More